Allan Davies

Allan Davies

Auto-generated profile, based on publicly available information

Allan Davies

Cardiovascular Department, John Hunter Hospital, Newcastle, NSW, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2020 in European Heart Journal
Verified
Journal Article
Closed access
ADAllan Davies
Allan Davies
KFKim Fox
Kim Fox
AGAlfredo R Galassi
Alfredo R Galassi
SBShmuel Banai
Shmuel Banai
SYSeppo Ylä-Herttuala
Seppo Ylä-Herttuala
TLThomas F Lüscher
Thomas F Lüscher
Despite the use of anti-anginal drugs and/or percutaneous coronary interventions (PCI) or coronary artery bypass grafting, the proportion of patients with coronary artery disease who have daily or weekly angina ranges from 2% to 24%. Refractory angina refers to long-lasting symptoms (for >3 months) due to established reversible ischaemia, which cannot be controlled by escalating medical therapy with the use of 2nd- and 3rd-line pharmacological agents, bypass grafting, or stenting. While there is uncertain prognostic benefit, the treatment of refractory angina is important to improve the quality of life of the patients affected. This review focuses on conventional pharmacological approaches to treating refractory angina, including guideline directed drug combination and dosages. The symptomatic and prognostic impact of advanced and novel revascularization strategies such as chronic total occlusion PCI, transmyocardial laser revascularization, coronary sinus occlusion, radiation therapy for recurrent restenosis, and spinal cord stimulation are also covered and recommendations of the 2019 ESC Guidelines on the Diagnosis and Management of Chronic Coronary Syndromes discussed. Finally, the potential clinical use of current angiogenetic and stem cell therapies in reducing ischaemia and/or pain is evaluated.

1 August 2018 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
MAMohammed S. Al-Omary
Mohammed S. Al-Omary
ADAllan J. Davies
Allan J. Davies
TETiffany-Jane Evans
Tiffany-Jane Evans
BBBruce Bastian
Bruce Bastian
PFPeter J. Fletcher
Peter J. Fletcher
ABAndrew Boyle
Andrew Boyle

31 October 2019 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
PWPatric Winzap
Patric Winzap
ADAllan Davies
Allan Davies
RKRoland Klingenberg
Roland Klingenberg
SOSlayman Obeid
Slayman Obeid
MRMarco Roffi
Marco Roffi
TLThomas F. Lüscher
Thomas F. Lüscher
Background: Hyperglycemia in the setting of an acute coronary syndrome (ACS) impacts short term outcomes, but little is known about longer term effects. We therefore designed this study to firstly determine the association between hyperglycemia and short term and longer term outcomes in patients presenting with ACS and secondly evaluate the prognostic role of diabetes, body mass index (BMI) and the novel biomarker Cyr61 on outcomes. Methods: The prospective Special Program University Medicine-Acute Coronary Syndrome (SPUM-ACS) cohort enrolled 2168 patients with ACS between December 2009 and October 2012, of which 2034 underwent PCI (93.8%). Patients were followed up for 12 months. Events were independently adjudicated by three experienced cardiologists. Participants were recruited from four tertiary hospitals in Switzerland: Zurich, Geneva, Lausanne and Bern. Participants presenting with acute coronary syndromes and who underwent coronary angiography were included in the analysis. Patients were grouped according to history of diabetes (or HbA1c greater than 6%), baseline blood sugar level (BSL; < 6, 6–11.1 and > 11.1 mmol/L) and body mass index (BMI). The primary outcome was major adverse cardiac events (MACE) which was a composite of myocardial infarction, stroke and all-cause death. Secondary outcomes included the individual components of the primary endpoint, revascularisations, bleeding events (BARC classification) and cerebrovascular events (ischaemic or haemorrhagic stroke or TIA). Results: Patients with hyperglycemia, i.e. BSL ≥ 11.1 mmol/L, had higher levels of C-reactive protein (CRP), white blood cell count (WBC), creatinine kinase (CK), higher heart rates and lower left ventricular ejection fraction (LVEF) and increased N-terminal pro-brain natriuretic peptide. At 30 days and 12 months, those with BSL ≥ 11.1 mmol/L had more MACE and death compared to those with BSL < 6.0 mmol/L or 6.0–11.1 mmol/L (HR-ratio 4.78 and 6.6; p < 0.001). The novel biomarker Cyr61 strongly associated with high BSL and STEMI and was independently associated with 1 year outcomes (HR 2.22; 95% CI 1.33–3.72; Tertile 3 vs. Tertile 1). Conclusions and relevance: In this large, prospective, independently adjudicated cohort of in all comers ACS patients undergoing PCI, both a history of diabetes and elevated entry glucose was associated with inflammation and increased risk of MACE both at short and long-term. The mediators might involve increased sympathetic activation, inflammation and ischemia as reflected by elevated Cyr61 levels leading to larger levels of troponin and lower LVEF. Trial registration Clinical Trial Registration Number: NCT01000701. Registered October 23, 2009

14 December 2017 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
SBStephen C. Brienesse
Stephen C. Brienesse
ADAllan J. Davies
Allan J. Davies
AKArshad Khan
Arshad Khan
ABAndrew Boyle
Andrew Boyle

28 September 2016 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
ADAllan Davies
Allan Davies
PGPrasad Gunaruwan
Prasad Gunaruwan
NCNicholas Collins
Nicholas Collins
MBMalcolm Barlow
Malcolm Barlow
NJNick Jackson
Nick Jackson
JLJames Leitch
James Leitch

1 May 2019 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
NJNicholas Jackson
Nicholas Jackson
MMMichael McGee
Michael McGee
WAWaheed Ahmed
Waheed Ahmed
ADAllan Davies
Allan Davies
JLJim Leitch
Jim Leitch
MBMalcolm Barlow
Malcolm Barlow